During the past 12 months, Adaptive Biotechnologies's average Total Assets Growth Rate was -9.10% per year.
During the past 3 years, the average Total Assets Growth Rate was -9.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 10.90% per year.
During the past 7 years, Adaptive Biotechnologies's highest 3-Year average Total Assets Growth Rate was 50.40%. The lowest was -9.70%. And the median was 19.10%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Adaptive Biotechnologies's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies (NAS:ADPT) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Sep. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Adaptive Biotechnologies's Asset Turnover for the quarter that ended in Sep. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Adaptive Biotechnologies Total Assets Related Terms
Thank you for viewing the detailed overview of Adaptive Biotechnologies's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADPT has been successfully added to your 